CONMED
CNMD
298 hedge funds and large institutions have $2.85B invested in CONMED in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 107 increasing their positions, 107 reducing their positions, and 60 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 107
3% less funds holding
Funds holding: 306 → 298 (-8)
2.9% less ownership
Funds ownership: 118.61% → 115.7% (-2.9%)
12% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 60
21% less call options, than puts
Call options by funds: $9.04M | Put options by funds: $11.4M
29% less capital invested
Capital invested by funds: $3.99B → $2.85B (-$1.14B)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$50.6M |
| 2 |
CB
Cooke & Bieler
Philadelphia,
Pennsylvania
|
+$37.4M |
| 3 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$30.8M |
| 4 |
ClearBridge Investments
New York
|
+$30.4M |
| 5 |
DM
Deerfield Management
New York
|
+$29.9M |
Top Sellers
CNMD Hedge Fund Activity: Q1 2024 in Review
298 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q1 2024, worth a combined $2.85B — down 29% from $3.99B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of CNMD and 53 opened new positions — a net loss of 7 holders — while 107 trimmed existing stakes and 107 added.
The largest buyer was Magnetar Financial, adding an estimated $50.6M. The largest seller was Capital Research Global Investors, cutting an estimated $116M.
- 298 institutional investors held CONMED (CNMD) as of Q1 2024, down from 306 in Q4 2023.
- Funds reported $2.85B of CONMED stock for Q1 2024, down 29% quarter-over-quarter.
- 53 funds opened new CONMED positions in Q1 2024 and 60 closed out, a net change of -7 holders.
- The largest CONMED buyer in Q1 2024 was Magnetar Financial, an estimated $50.6M added.
- The largest CONMED seller in Q1 2024 was Capital Research Global Investors, an estimated $116M sold.
Based on aggregated 13F filings for Q1 2024.